Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.48 |
| ▸ | CCR6 | P51684 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 8/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1141304 | 1.00 | MAP3K12 (0.51) | MAP3K12HCRTR1CCR6SYKPOLB | |
| SCHEMBL1835677 | 0.86 | KDM4E (0.52) | MAP3K12HCRTR1SYKHCRTR2 | |
| SCHEMBL1141246 | 0.84 | POLB (0.45) | HCRTR1POLB | |
| SCHEMBL1141245 | 0.84 | POLB (0.45) | HCRTR1POLB | |
| SCHEMBL1141144 | 0.83 | HCRTR1 (0.49) | HCRTR1POLBHCRTR2 | |
| SCHEMBL1141147 | 0.83 | HCRTR1 (0.49) | HCRTR1POLBHCRTR2 | |
| SCHEMBL1141554 | 0.82 | KMT2A (0.47) | HCRTR1SYKPOLB | |
| SCHEMBL1141551 | 0.82 | KMT2A (0.47) | HCRTR1SYKPOLB | |
| SCHEMBL1141105 | 0.82 | GFER (0.47) | HCRTR1POLB | |
| SCHEMBL20144856 | 0.82 | HCRTR1 (0.66) | MAP3K12HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318367-B1 | PIPERIDINE AND PYRROLIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-03-20 | — | — | EP | claimed |
| EP-2318367-A1 | PIPERIDINE AND PYRROLIDINE COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2011-05-11 | — | — | EP | claimed |
| US-20110039857-A1 | PIPERIDINE AND PYROOLIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-17 | — | — | US | claimed |
| WO-2009133522-A1 | PIPERIDINE AND PYRROLIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-11-05 | — | — | WO | claimed |
| EP-2318367-B1 | PIPERIDINE AND PYRROLIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-20110039857-A1 | PIPERIDINE AND PYROOLIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039857-A1 | PIPERIDINE AND PYROOLIDINE COMPOUNDS | HCRTR1, HCRTR2, NPY1R | MAP3K12 3893/4885HCRTR1 1/4885CCR6 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.